Pharvaris NV (NASDAQ: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema, on Tuesday announced positive top-line results from its CHAPTER-3 pivotal Phase 3 study of deucrictibant extended-release (XR) for preventing hereditary angioedema (HAE) attacks.
The company plans to use the data to support marketing authorisation applications from the first half of 2027.
The global, double-blind, placebo-controlled study enrolled 85 participants across 21 countries and evaluated once-daily deucrictibant XR for 24 weeks. Participants receiving deucrictibant XR recorded an 83% reduction in mean monthly attack rate versus placebo (p
Lynch Regenerative Medicine's Phase IIb clinical trial of rhPDGF-BB injection cleared by FDA
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
GSK wins US FDA approval for chronic hepatitis B treatment Hibsago
Summit Therapeutics and ECOG-ACRIN launch Phase II/III trial collaboration for biliary tract cancer
RxMP Therapeutics secures DARPA contract worth up to USD10.7m
TNutra launches NeuraLegend brain health supplements
Health Canada approves AbbVie psoriasis treatment for children
Oracle partners AstraZeneca for AI-enabled healthcare innovation
Eli Lilly and Company reports positive one-year results for Omvoh in paediatric ulcerative colitis
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
GSK reports 61% response rate for investigational lung cancer drug